Screener
Halozyme Therapeutics HALO Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's current debt?
- Halozyme Therapeutics (HALO) reported current debt of $208.97M in Q2 2026.
- What is the long-term trend for Halozyme Therapeutics's current debt?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's current debt has grown at a -100.0% compound annual growth rate (CAGR), from $397.23M to $0.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Halozyme Therapeutics's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude